Chemical Structure (Des Structure)
Desvenlafaxine Tablet, Extended Release
Product Images NDC 71335-1815
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 71335-1815). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Figure 1)
This is a report of PK (pharmacokinetic) parameters for a drug, indicating the geometric mean ratio (and 90% CI) for Cmax (maximum plasma concentration) and AUC (area under the plasma concentration-time curve) in different populations. The populations evaluated are those with renal impairment (mild, moderate, severe, and end-stage renal disease), hepatic impairment (mild, moderate, and severe), and different demographics (gender and age).*
Figure 2 (Figure 2)
The text describes a study that involved the use of CYP3A4 inhibitors, specifically ketoconazole, and its effect on Cmax levels. The results are presented using geometric mean ratios and 90% confidence intervals. The study showed a change in Cmax levels with the use of ketoconazole compared to the reference group.*
Figure 3 (Figure 3)
This is a table presenting PK geometric mean ratio (90% ClI) for different drug interactions with Desvenlafaxine, a CYP2D6 & CYP3A4 substrate. The table presents the change relative to reference for the different interactions including CYP2D6 and CYP3A4 substrates such as Desipramine and Midazolam, Tamoxifen, and Aripiprazole. The data in the table shows the Cmax and AUC values for each interaction.*
Figure 4 (Figure 4)
The text describes a graph that shows the estimated proportion of patients with relapse over time in days from randomization for Desvenlafaxine Extended-Release Tablets 50 mg and placebo. The proportions are represented by percentages on the vertical axis and time is represented by days on the horizontal axis. However, there is no information on the timeframe or conditions of the study from which the data was obtained.*
Figure 5 (Figure 5)
This appears to be a chart showing the estimated proportion of patients who have relapsed over time (in days from randomization) for Desvenlafaxine Extended-Release Tablets compared to a placebo. The chart also includes tick marks for the number of patients who have relapsed at various time points.*
Label (Lbl713351815)
This appears to be a label for a medication package, containing information on the packaging company, the medication name, manufacturer, quantity, expiration date and storage instructions. There is also a warning to keep the medication out of reach of children.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
